EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration

Benjamin Ng, Hema Kolli, Naduviledeth Ajith Kumar, Matthew Azzopardi iD, Abison Logeswaran, Julius Buensalido, Bushra Mushtaq, Randhir Chavan, Yu Jeat Chong

Life · 29.01.2024 · 14 (2) · 193

DOI: 10.3390/life14020193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 29.01.2024. Verfasst von Benjamin Ng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QH, UK. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Faricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict these outcomes; and obtain patient subjective experience on this new injection. This is a retrospective case review with clinical and imaging data from a tertiary referral unit (Birmingham and Midland Eye Centre, UK), involving patients who were switched to faricimab between 1 January and 1 December 2023. In all, 63 eyes (54 patients) with a mean age of 79.2 ± 7.8 and mean of 41.5 ± 22.4 previous anti-VEGF injections were analysed. With a mean of 4.81 ± 1.16 faricimab injections over 6.98 ± 1.75 months, post-treatment visual acuity was logMAR 0.49 ± 0.36 and central macular thickness (CMT) was 320.3 ± 97.9 µm. After first dose, 39.1% achieved complete dryness and 89.1% had anatomical improvement. Presence of subretinal fluid was a predictor of better functional outcomes (p = 0.001, β = −0.182), while initial CMT predicted better anatomical outcomes (p = 0.001, β = 0.688). Compared to their experiences of previous anti-VEGF injections, 89% of patients reported no more discomfort and 87.0% experienced no more floaters, photopsia, or bubbles post-injection. Faricimab switching has anatomical efficacy but limited functional improvement in treatment-refractory AMD. Patient experiences of faricimab compared to previous injections were overall positive.

Schlagwörter

Stichwörter der Autor:innen

Ang-2anti-VEGFfaricimabneovascular age-related macular degeneration

Autor:innen und Institutionen

  • Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QH, UK.
  • Christ Church, University of Oxford, St. Aldate's, Oxford OX1 1DP, UK.
  • Royal Free Hospital, Pond Street, London NW3 2QG, UK.
  • Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK.

ORCID-Profile: Matthew Azzopardi

Zitieren

APA

Ng, B., Kolli, H., Ajith Kumar, N., Azzopardi, M., Logeswaran, A., Buensalido, J., Mushtaq, B., Chavan, R., & Chong, Y. J. (2024). Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration. Life, 14(2), 193. https://doi.org/10.3390/life14020193

Vancouver

Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J, et al. Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration. Life. 2024;14(2):193. doi:10.3390/life14020193

BibTeX
@article{Ng2024,
  author = {Ng, Benjamin and Kolli, Hema and Ajith Kumar, Naduviledeth and Azzopardi, Matthew and Logeswaran, Abison and Buensalido, Julius and Mushtaq, Bushra and Chavan, Randhir and Chong, Yu Jeat},
  title = {Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration},
  journal = {Life},
  year = {2024},
  volume = {14},
  number = {2},
  pages = {193},
  doi = {10.3390/life14020193}
}
Kostenlos starten →